User profiles for David Joske
 | David JoskeUWA Verified email at health.wa.gov.au Cited by 7018 |
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre …
…, D Huebner, M Little, S Whittaker, M Duvic, D Joske… - The Lancet, 2017 - thelancet.com
Background Cutaneous T-cell lymphomas are rare, generally incurable, and associated
with reduced quality of life. Present systemic therapies rarely provide reliable and durable …
with reduced quality of life. Present systemic therapies rarely provide reliable and durable …
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate …
Imatinib-treated chronic myeloid leukemia (CML) patients with acquired resistance commonly
have detectable BCR-ABL kinase domain mutations. It is unclear whether patients who …
have detectable BCR-ABL kinase domain mutations. It is unclear whether patients who …
[HTML][HTML] Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
Purpose Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic
agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of …
agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of …
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
…, SM Steinberg, S Smith, D Joske… - Blood, The Journal …, 2011 - ashpublications.org
Romidepsin (depsipeptide or FK228) is a histone deacetylase inhibitor, one of a new class
of agents active in T-cell lymphoma. A phase 2 trial was conducted in cutaneous (CTCL) and …
of agents active in T-cell lymphoma. A phase 2 trial was conducted in cutaneous (CTCL) and …
A pilot randomized trial comparing CD34‐selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis
…, P Cannell, R Will, S Rule, D Joske… - Arthritis & …, 2002 - Wiley Online Library
Objective Evidence from animal studies, case reports, and phase I studies suggests that
hemopoietic stem cell transplantation (HSCT) can be effective in the treatment of rheumatoid …
hemopoietic stem cell transplantation (HSCT) can be effective in the treatment of rheumatoid …
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
…, R Filshie, K Bradstock, R Herrmann, D Joske… - Blood, 2004 - ashpublications.org
Mutations within the BCR-ABL kinase domain in imatinib-treated chronic myeloid leukemia (CML)
are the main mechanism of acquired resistance. The early detection of mutations …
are the main mechanism of acquired resistance. The early detection of mutations …
Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
…, S Durrant, H Januszewicz, D Joske… - Blood, The Journal …, 2008 - ashpublications.org
We conducted a trial in 103 patients with newly diagnosed chronic phase chronic myeloid
leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for …
leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for …
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR.
OBJECTIVE: Since 1996, autologous hemopoietic stem cell transplantation (HSCT) has
been used to treat severe rheumatoid arthritis (RA). To date, published reports have been …
been used to treat severe rheumatoid arthritis (RA). To date, published reports have been …
[HTML][HTML] Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study
Background: Patients with chronic lymphocytic leukaemia (CLL) are known to have increased
risks of second cancer. The incidence of second cancers after CLL has not been reported …
risks of second cancer. The incidence of second cancers after CLL has not been reported …
Lymphoid neoplasm incidence by WHO subtype in Australia 1982–2006
MT Van Leeuwen, JJ Turner, DJ Joske… - … journal of cancer, 2014 - Wiley Online Library
There are limited data characterizing the subtype‐specific incidence of lymphoid neoplasms
in the World Health Organization (WHO) Classification era. Data were obtained on all …
in the World Health Organization (WHO) Classification era. Data were obtained on all …